CR10414A - Tratamientos de las alergias oculares - Google Patents

Tratamientos de las alergias oculares

Info

Publication number
CR10414A
CR10414A CR10414A CR10414A CR10414A CR 10414 A CR10414 A CR 10414A CR 10414 A CR10414 A CR 10414A CR 10414 A CR10414 A CR 10414A CR 10414 A CR10414 A CR 10414A
Authority
CR
Costa Rica
Prior art keywords
eye allergy
allergy treatments
treatments
eye
alcaftadine
Prior art date
Application number
CR10414A
Other languages
English (en)
Inventor
Parasrampuria Jagdish
Ingerman Avner
Janssens Frans
Megens Anton
Original Assignee
Vistakon Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceuticals Llc filed Critical Vistakon Pharmaceuticals Llc
Publication of CR10414A publication Critical patent/CR10414A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones, kits y metodos para el tratamiento o prevencion de las alergias e inflamacion oculares y los sintomas de las mismas, que comprenden alcaftadina o una sal farmaceuticamente aceptable de la misma.
CR10414A 2006-03-31 2008-10-30 Tratamientos de las alergias oculares CR10414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
CR10414A true CR10414A (es) 2009-02-23

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10414A CR10414A (es) 2006-03-31 2008-10-30 Tratamientos de las alergias oculares

Country Status (30)

Country Link
US (7) US8664215B2 (es)
EP (2) EP2004196B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK3150209T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2752823T3 (es)
HK (1) HK1131331A1 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL3150209T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI578990B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004196B1 (en) 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2009061431A2 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
PT2408453T (pt) 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
JPWO2019026992A1 (ja) * 2017-08-03 2020-06-18 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
EP3740191B1 (en) 2018-01-18 2021-04-28 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
KR20230024928A (ko) 2020-06-15 2023-02-21 알켐 라보라토리즈 리미티드 알카프타딘과 코르티코스테로이드의 병용
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device
US20240173331A1 (en) 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
TW202408472A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
WO2024204749A1 (ja) * 2023-03-31 2024-10-03 ロート製薬株式会社 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
US5393753A (en) 1990-10-10 1995-02-28 Schering Corporation Substituted imidazobenzazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077302A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
EP2010143B1 (en) 2006-03-17 2015-08-12 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
EP2004196B1 (en) 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments

Also Published As

Publication number Publication date
ZA200809327B (en) 2009-12-30
AU2007234957A1 (en) 2007-10-18
NZ571690A (en) 2011-09-30
CA2648115A1 (en) 2007-10-18
EP3150209B1 (en) 2019-07-24
DK2004196T3 (en) 2016-09-05
US20240058355A1 (en) 2024-02-22
MY153669A (en) 2015-03-13
US20170065605A1 (en) 2017-03-09
BRPI0710085B1 (pt) 2019-12-17
CL2007000916A1 (es) 2008-01-25
MX2008012657A (es) 2009-02-19
EP2004196B1 (en) 2016-06-29
WO2007117971A3 (en) 2007-12-27
ES2752823T3 (es) 2020-04-06
US20080051385A1 (en) 2008-02-28
JP5292277B2 (ja) 2013-09-18
UY30254A1 (es) 2007-08-31
US10617695B2 (en) 2020-04-14
KR101321731B1 (ko) 2013-10-30
TW201446249A (zh) 2014-12-16
US20210030762A1 (en) 2021-02-04
BRPI0710085A2 (pt) 2011-08-23
TW200815016A (en) 2008-04-01
JP2009533333A (ja) 2009-09-17
WO2007117971A2 (en) 2007-10-18
AR060278A1 (es) 2008-06-04
PE20080053A1 (es) 2008-03-10
CN102895234A (zh) 2013-01-30
TWI450721B (zh) 2014-09-01
EA016221B1 (ru) 2012-03-30
JP2015131820A (ja) 2015-07-23
AU2007234957B2 (en) 2012-12-13
PL2004196T3 (pl) 2017-01-31
JP6039716B2 (ja) 2016-12-07
NO341147B1 (no) 2017-09-04
PL3150209T3 (pl) 2020-03-31
BRPI0710085B8 (pt) 2021-05-25
ECSP088786A (es) 2009-01-30
ES2594655T3 (es) 2016-12-21
IL194473A0 (en) 2009-08-03
DK3150209T3 (da) 2019-10-28
CA2648115C (en) 2015-03-24
EA200870396A1 (ru) 2009-04-28
US20120094978A1 (en) 2012-04-19
JP2013144703A (ja) 2013-07-25
JO3358B1 (ar) 2019-03-13
EP2004196A2 (en) 2008-12-24
IL194473A (en) 2016-04-21
SG170044A1 (en) 2011-04-29
HK1131331A1 (en) 2010-01-22
US20230181594A1 (en) 2023-06-15
EP3150209A1 (en) 2017-04-05
NO20084593L (no) 2008-10-29
TWI578990B (zh) 2017-04-21
KR20080110881A (ko) 2008-12-19
US20140107102A1 (en) 2014-04-17
US8664215B2 (en) 2014-03-04
NI200800261A (es) 2012-10-30

Similar Documents

Publication Publication Date Title
AR060278A1 (es) Tratamientos de las alergias oculares
CR10347A (es) Anticuerpos contra el peptidob-amiloide
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
CR10226A (es) Combinaciones del inhibidor de ang2 y vegf
EA200901211A1 (ru) Антигены белка с5 и их применение
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR9580A (es) Inhibidores de la actividad akt
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
SV2009002863A (es) Compuestos anti-hipercolesterolemicos
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas